Physician profile
John P Morcos
NPI 1013052216
$7,562.96
in general payments reported to CMS, 2019-2025
15 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,519 · 2020: $27.42 · 2021: $1,493 · 2022: $236 · 2023: $68.54 · 2024: $87.44 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $177 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $177.43 |
| Education | $110.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,608.09 | 2019-2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $1,696.79 | 2019-2023 | Eliquis |
| Dendreon Pharmaceuticals LLC | $1,635.22 | 2019 | |
| Janssen Biotech, INC. | $103.32 | 2022-2024 | Erleada |
| Pharmacyclics LLC, An Abbvie Company | $99.00 | 2019 | |
| Incyte Corporation | $99.00 | 2019 | |
| Shockwave Medical, INC | $69.62 | 2022 | |
| Novartis Pharmaceuticals Corporation | $45.04 | 2023-2025 | |
| Mirati Therapeutics, INC. | $42.00 | 2023 | Krazati |
| Exelixis INC. | $41.14 | 2024 | Cabometyx |
| Blueprint Medicines Corporation | $32.19 | 2025 | Ayvakit |
| Seagen INC. | $27.42 | 2020 | |
| Clovis Oncology, INC. | $24.52 | 2019 | |
| Array Biopharma INC | $19.98 | 2024 | Tukysa, Braftovi, Mektovi |
| Bayer Healthcare Pharmaceuticals INC. | $19.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morcos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.